Scarica l'app Stockscreener
221.20
0.63%
1.39
Dopo l'orario di chiusura:
220.77
-0.43
-0.19%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$219.81
Aprire:
$220.72
Volume 24 ore:
3.00M
Relative Volume:
0.73
Capitalizzazione di mercato:
$155.50B
Reddito:
$24.78B
Utile/perdita netta:
$3.68B
Rapporto P/E:
42.75
EPS:
5.1743
Flusso di cassa netto:
$5.29B
1 W Prestazione:
-0.00%
1M Prestazione:
+10.52%
6M Prestazione:
+16.66%
1 anno Prestazione:
+9.26%
Intervallo 1D:
$219.11
$221.42
Intervallo di 1 settimana:
$211.72
$227.61
Portata 52W:
$160.93
$242.80
Danaher Corp Stock (DHR) Company Profile
Nome
Danaher Corp
Settore
Industria
Telefono
(202) 828-0850
Indirizzo
2200 PENNSYLVANIA AVE. N.W., WASHINGTON, DC
Compare DHR vs TMO, NTRA, A, IQV
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DHR
Danaher Corp
|
221.20 | 155.50B | 24.78B | 3.68B | 5.29B | 5.1743 |
TMO
Thermo Fisher Scientific Inc
|
662.24 | 244.86B | 45.20B | 6.87B | 6.75B | 18.19 |
NTRA
Natera Inc
|
397.77 | 57.34B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
171.33 | 48.30B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
262.21 | 43.16B | 16.63B | 1.39B | 2.12B | 8.0674 |
Danaher Corp Stock (DHR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-09-09 | Ripresa | UBS | Buy |
| 2026-06-11 | Iniziato | Piper Sandler | Neutral |
| 2026-06-03 | Iniziato | DZ Bank | Buy |
| 2026-06-02 | Ripresa | Wolfe Research | Peer Perform |
| 2026-05-26 | Ripresa | Citigroup | Buy |
| 2026-05-15 | Ripresa | RBC Capital Mkts | Outperform |
| 2025-12-09 | Iniziato | Goldman | Buy |
| 2025-12-02 | Iniziato | Morgan Stanley | Overweight |
| 2025-10-08 | Downgrade | Rothschild & Co Redburn | Buy → Neutral |
| 2025-07-11 | Aggiornamento | Scotiabank | Sector Perform → Sector Outperform |
| 2025-04-10 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2025-03-21 | Aggiornamento | Goldman | Neutral → Buy |
| 2025-03-14 | Aggiornamento | Stifel | Hold → Buy |
| 2025-02-03 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2024-12-23 | Iniziato | Scotiabank | Sector Perform |
| 2024-12-19 | Iniziato | Guggenheim | Buy |
| 2024-12-13 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-10-31 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2024-10-01 | Iniziato | Stephens | Overweight |
| 2024-08-28 | Iniziato | Wells Fargo | Equal Weight |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-04-17 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-01-24 | Downgrade | Barclays | Overweight → Equal Weight |
| 2023-12-18 | Iniziato | HSBC Securities | Hold |
| 2023-12-13 | Ripresa | Wolfe Research | Peer Perform |
| 2023-12-07 | Downgrade | Goldman | Buy → Neutral |
| 2023-07-19 | Iniziato | Raymond James | Outperform |
| 2023-05-01 | Iniziato | SVB Securities | Outperform |
| 2023-04-26 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-04-18 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-01-05 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2022-12-14 | Iniziato | Deutsche Bank | Buy |
| 2022-10-24 | Downgrade | The Benchmark Company | Buy → Hold |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-08-17 | Ripresa | Bernstein | Outperform |
| 2022-07-20 | Iniziato | UBS | Buy |
| 2022-06-01 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-01-11 | Iniziato | Bernstein | Outperform |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-09-10 | Reiterato | BofA Securities | Buy |
| 2021-08-05 | Ripresa | Credit Suisse | Outperform |
| 2021-07-23 | Reiterato | Goldman | Buy |
| 2021-07-16 | Iniziato | The Benchmark Company | Buy |
| 2021-04-07 | Ripresa | Robert W. Baird | Outperform |
| 2021-03-03 | Ripresa | Barclays | Overweight |
| 2020-12-02 | Iniziato | Goldman | Buy |
| 2020-11-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2020-06-16 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-04-02 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2020-03-26 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-02-03 | Reiterato | Needham | Buy |
| 2020-01-08 | Iniziato | Wells Fargo | Overweight |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-11-15 | Ripresa | Stifel | Hold |
| 2019-10-28 | Reiterato | Needham | Buy |
| 2019-10-14 | Ripresa | Credit Suisse | Outperform |
| 2019-07-19 | Reiterato | Needham | Buy |
| 2019-06-11 | Iniziato | Piper Jaffray | Neutral |
| 2019-05-30 | Iniziato | Wolfe Research | Outperform |
| 2019-04-17 | Reiterato | Needham | Buy |
| 2019-02-28 | Reiterato | Needham | Buy |
| 2019-02-25 | Aggiornamento | Janney | Neutral → Buy |
| 2019-01-03 | Iniziato | Needham | Buy |
| 2018-04-20 | Reiterato | Stifel | Buy |
Mostra tutto
Danaher Corp Borsa (DHR) Ultime notizie
Danaher stock at USD 219.87 on October 9, 2026 - AD HOC NEWS
Danaher accelerates Life Sciences research with new AI-powered autonomous lab - BioSpectrum Asia
Danaher Corp. stock at EUR 196.80, market value USD 154.7 billion - AD HOC NEWS
Barclays raises target for Danaher stock to USD 255.00 - AD HOC NEWS
Did Danaher’s (DHR) New AI-Powered Autonomous Lab at Abcam Just Redefine Its Innovation Edge? - Yahoo Finance
Danaher (DHR) Stock May Be 4% Undervalued Despite AI Lab Launch - Yahoo Finance
Is Danaher (DHR) Undervalued As Its New AI Lab Pushes Faster Antibody Development? - Yahoo Finance
Danaher (DHR) Launched Its First AI Powered Autonomous Laboratory - Yahoo Finance
Danaher Accelerates Life Sciences Research with New AI-powered Autonomous Lab - HPCwire
Venkatesan leaves head of investment role at Danaher - Global Venturing
Danaher Corp. stock outperforms competitors on strong trading day - MarketWatch
Life sciences firm Danaher to launch AI-powered autonomous research lab in 2027 - Reuters
Top Stock Reports for AMD, Palo Alto & ConocoPhillips - Zacks Investment Research
Danaher is launching an AI-powered autonomous lab for drug discovery - Quartz
Danaher stock rises 2% on AI-powered autonomous lab plans - Yahoo Finance
Danaher Corporation Announces Plans to Launch Its First Ai-Powered Autonomous Lab - marketscreener.com
Danaher to Launch AI-Backed Autonomous Lab - www.marketscreener.com
Life sciences firm Danaher to launch AI-powered autonomous research lab in 2027 - The Lufkin Daily News
Life sciences firm Danaher to launch AI-powered autonomous research lab in 2027 - Wichita Eagle
Life sciences firm Danaher to launch AI-powered autonomous research lab in 2027 - marketscreener.com
Danaher plans AI-powered autonomous lab for antibody research By Investing.com - Investing.com Canada
Danaher launches AI-powered autonomous lab to s... - Pluang
A planned lab could make up to 10 times as many research tools each year as it scales. - Stock Titan
Danaher Accelerates Life Sciences Research with New AI-powered Autonomous Lab - Yahoo Finance
Danaher Accelerates Life Sciences Research with New AI-powered Autonomous Lab - TradingView
Danaher (DHR) Draws Fresh RBC Backing, Is The Valuation Still Compelling? - Simply Wall Street
Danaher Corp. stock outperforms competitors despite losses on the day - MarketWatch
Global Microfluidics Market by Product Type, Application, End User, and Region, 2026-2036 | $48.04 Billion Opportunity Driven by Point-of-Care Diagnostics and Automation - GlobeNewswire Inc.
RBC Capital raises Danaher stock price target on peer valuation By Investing.com - Investing.com South Africa
Danaher Corp (DHR) Stock Up 3.3% and Still Undervalued -- GF Sco - GuruFocus
Danaher Corporation stock reports 5.5 percent revenue growth for Q2 2026 - AD HOC NEWS
Danaher Corp. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
DHR|Danaher Corp|Price:221.230|Chg%:+7.170 - TradingKey
Danaher Corp Stock (DHR) Moved Up by 3.32% on Oct 5: What Investors Need To Know - TradingKey
Danaher Corporation, Illumina, Reliance - TradingView
Danaher Corporation, Illumina, Reliance - TradingView
Danaher's Multiple Now in Line With Peers, RBC Says - marketscreener.com
Danaher's Multiple Now in Line With Peers, RBC Says - Yahoo Finance
Europe Point of Care Diagnostics Market Size and Forecast, 20212031 | Market to Reach US$21.4 Billion by 2031 as Rapid Testing and Molecular Innovation Drive 13.4% CAGR - GlobeNewswire Inc.
Danaher Corporation, Illumina, Reliance - TradingView
Global Oligonucleotide Synthesis Reagents Market Size, Share, and Forecast, 2026-2033 | Therapeutics Demand Fuels 11.9% CAGR and USD 1.75 Billion Opportunity - GlobeNewswire Inc.
Cell and Gene Therapy Biomanufacturing MarketSize, Share, and Forecast, 2026-2031 | Automation, Viral Vectors, and CDMO Expansion Drive 11.7% CAGR to $8.7 Billion - GlobeNewswire Inc.
Magnetic Beads MarketGlobal Forecast and Growth Opportunities, 2026-2032 | Automation, Genomics, and Molecular Diagnostics Drive 7.91% CAGR Toward USD 6.18 Billion - GlobeNewswire Inc.
DANAHER CORPORATION : RBC RAISES TARGET PRICE TO $250 FROM $215 - Moomoo
Options on 36,856 shares at $194.78 are among the Danaher (DHR) strategy chief's holdings. - Stock Titan
DANAHER CORP (DHRC.VI) Q2 FY2026 earnings call transcript - Yahoo Finance
Parker-Hannifin Benefits From Business Strength Amid Headwinds - Zacks Investment Research
Danaher Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Danaher Slides as Investors Weigh Leadership Change and Prior Growth Outlook Reset - Quiver Quantitative
Danaher Corp Stock (DHR) Moved Down by 3.29% on Oct 1: What Investors Need To Know - TradingKey
Danaher Corp Azioni (DHR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Danaher Corp Azioni (DHR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Rainer M. Blair | Officer |
Aug 21 '26 |
Proposed Sale |
218.85 |
58,255 |
12,749,107 |
0 |
| Zerhouni Elias A. | Director |
Jul 15 '26 |
Option Exercise |
71.88 |
3,298 |
237,060 |
46,484 |
| FILLER LINDA | Director |
Jul 15 '26 |
Option Exercise |
71.88 |
3,298 |
237,060 |
28,010 |
| SCHWIETERS JOHN T | Former Director |
Jul 14 '26 |
Proposed Sale |
199.59 |
3,298 |
658,254 |
0 |
| SPOON ALAN G | Director |
May 01 '26 |
Proposed Sale |
174.67 |
1,358 |
237,207 |
0 |
| SPOON ALAN G | Director |
May 01 '26 |
Option Exercise |
71.88 |
3,298 |
237,060 |
125,452 |
| SPOON ALAN G | Director |
May 01 '26 |
Sale |
174.67 |
1,358 |
237,207 |
124,094 |
| Milosevich Gregory M | Executive Vice President |
Feb 19 '26 |
Option Exercise |
58.59 |
1,320 |
77,339 |
6,419 |
| Milosevich Gregory M | Executive Vice President |
Feb 19 '26 |
Sale |
208.01 |
1,320 |
274,575 |
5,099 |
| Milosevich Gregory M | Officer |
Feb 19 '26 |
Proposed Sale |
208.01 |
1,320 |
274,575 |
0 |
0.64%
0.73%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):